samedan logo
 
 
 
spacer
home > ebr > spring 2021 > endotoxins – the unwanted contaminants in biomaterials for regenerative medicines
PUBLICATIONS
European Biopharmaceutical Review

Endotoxins – The Unwanted Contaminants in Biomaterials for Regenerative Medicines

In biomedical applications, the presence of lipopolysaccharides (LPS) is a significant cause for concern. What are LPS and the associated risks?

Elien Gevaert: LPS, also known as endotoxins, are toxins found in the outer membrane of gram-negative bacteria. They can initiate strong immune responses, mainly via interaction with Toll-like receptor 4 (TLR-4) expressed on the cell membranes of a variety of cell types. The human body can react to the presence of LPS with fever, chills, shaking, and sometimes respiratory symptoms. The presence of LPS in the circulation can lead to endotoxemia and possible anaphylactic shock, while chronic exposure to LPS can result in systemic inflammation and can aggravate existing diseases or create novel health problems.

Unsurprisingly, the FDA imposes strict regulations on the levels of endotoxins allowed for medical devices. For devices targeting the cardiovascular system, the endotoxin limit is 20 endotoxin units (EU)/device, while for those in contact with cerebrospinal fluid, the limit is even lower, at 2.15 EU/device.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Elien Gevaert holds a Master of Science in Biochemistry and Biotechnology. After obtaining a PhD in Biomedical Sciences in the field of liver tissue engineering, she joined the upper airways research lab at the University of Ghent/University Hospital, Belgium. There, Elien investigated the immunological mechanisms underlying airway inflammatory diseases as a postdoc for six years. Her academic career has resulted in more than 30 scientific publications in leading scientific journals. In 2020, she joined Rousselot as Principal Scientist. In her current position, she leads and coordinates several R&D projects with the aim of developing new and innovative gelatin-based products for nutritional or biomedical applications.
Print this page
Send to a friend
Privacy statement
News and Press Releases

H&T Presspart announces partnership with BIOCORP for the InspairTM digital technology

H&T Presspart (a division of the German based Heitkamp & Thumann Group), announces today that a new partnership deal has been signed with BIOCORP, a French based company specialised in the development and manufacture of medical devices and connected healthcare solutions, whereby H&T Presspart is licensed to sell and promote BIOCORP’s InspairTM smart add-on device for metered-dose inhalers.
More info >>

White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement